Find a story

Search Spins

Search titles, summaries, and missing voices across published articles — press releases, announcements, and media coverage.

7 results for “GLP-1”

SPIN Processed News Frame: The Fog

Launch HN: RonanRX (YC S26) – Personalized Peptides and GLP-1s

A Y Combinator–backed startup named RonanRX announced its launch on Hacker News, claiming to offer personalized peptides and GLP-1 analogs for health optimization, though the post contains no verifiable product details, clinical validation, regulatory status, or operational evidence.

Spin 35% Needs Evidence
Hacker News Front Page

Sep 3, 2026

SPIN Processed News Frame: The Stampede

US nutrition startup Berry Street merges with India’s Healthify as GLP-1 trends upwards

A US nutrition startup and an Indian health tech company merged, appointing dual co-CEOs, amid rising market attention to GLP-1 medications.

Spin 82% Claim Present in Source AI Risk Moderate
TechCrunch

Aug 24, 2026

SPIN Processed News Frame: none

5 Hidden Side Effects Of GLP-1s To Consider Before Treatment - Forbes

The article is a health-focused consumer advisory about side effects of GLP-1 medications, misattributed to 'Forbes AI / SaaS' and erroneously ingested into an AI technology feed.

Spin 0% Needs Evidence
Forbes AI / SaaS via Google News

Aug 6, 2026

SPIN Processed Press Release Frame: The Hype

Ascletis Submits Two IND Applications to the U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulation of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35

Ascletis submitted two Investigational New Drug (IND) applications to the U.S. FDA for obesity treatments ASC36 and ASC36_35 FDC — a co-formulated, once-monthly injectable targeting three receptors — positioning itself in the competitive GLP-1 analog space.

Spin 75% Claim Present in Source AI Risk High
PR Newswire Technology

Published Jul 6, 2026 · Analyzed Jul 8, 2026

SPIN Processed Press Release Frame: The Hype

Evolv Launches Evolv Grow, a Next-Generation Oral GHK-Cu Hair Growth Supplement for Men and Women Powered by EV2 Peptide™

Evolv launched Evolv Grow, an oral GHK-Cu hair growth supplement marketed for men and women, citing a 12-week placebo-controlled study and retail availability via its website and Equinox Hotel Spa.

Spin 85% Claim Present in Source AI Risk High
PR Newswire Technology

Published Jul 2, 2026 · Analyzed Jul 5, 2026

SPIN Processed News Frame: The Hype

Just About Anyone Can Sell You GLP-1s Online Now

Telehealth platforms allow anyone to sell GLP-1s online, including non-medical professionals.

Spin 80% Partially Verified In Source
WIRED Business

Published Jul 1, 2026 · Analyzed Jul 4, 2026

SPIN Processed News Frame: The Fog

Study: Women are more likely to get hired after taking GLP-1s - Fast Company

The article falsely claims a causal relationship between women taking GLP-1 drugs and increased hiring likelihood, misrepresenting or fabricating a study that does not exist in credible scientific literature.

Spin 92% Needs Evidence AI Risk High
Fast Company AI via Google News

Published Jun 30, 2026 · Analyzed Jul 7, 2026